You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 9,499,545

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,499,545 protect, and when does it expire?

Patent 9,499,545 protects QULIPTA and UBRELVY and is included in two NDAs.

This patent has sixty-four patent family members in forty-three countries.

Summary for Patent: 9,499,545

Scope and claims summary:

Title:	Piperidinone carboxamide azaindane CGRP receptor antagonists
Abstract:	The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Inventor(s):	Bell; Ian M. (Harleysville, PA), Fraley; Mark E. (North Wales, PA), Gallicchio; Steven N. (Horsham, PA), Ginnetti; Anthony (Perkasie, PA), Mitchell; Helen J. (Richboro, PA), Paone; Daniel V. (Lansdale, PA), Staas; Donnette D. (Harleysville, PA), Wang; Cheng (Fort Washington, PA), Zartman; C. Blair (Hatfield, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	14/485,259
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,499,545

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS	⤷ Subscribe
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS	⤷ Subscribe
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-003	Sep 28, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,499,545

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2638042	⤷ Subscribe	301248	Netherlands	⤷ Subscribe
European Patent Office	2638042	⤷ Subscribe	PA2023532	Lithuania	⤷ Subscribe
European Patent Office	2638042	⤷ Subscribe	CR 2023 00033	Denmark	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.